Seattle Genetics establishes relationship with Albany Molecular

Seattle Genetics has entered into a preferred provider agreement with Albany Molecular Research for manufacturing of its proprietary drug-linker system.

The system, comprised of cell-killing drugs and stable linkers, is utilised in Seattle Genetics' antibody-drug conjugate (ADC) technology. The arrangement secures rights for Seattle Genetics' ADC licensees to work directly with AMRI on manufacturing campaigns to obtain cGMP supplies of drug-linker units to support future clinical trials of products utilising the ADC technology.

'Our expanded relationship with Albany Molecular provides our collaborators with a key component of the supply chain for ADC products they are developing by enabling them to obtain materials produced through an established manufacturing process,' stated Dr Clay Siegall, president and ceo of Seattle Genetics. 'Albany Molecular has demonstrated its capabilities in process development, scale-up and manufacturing of synthetic drug-linker systems employed in our industry-leading ADC technology. This arrangement will support the continued work by our collaborators to advance their ADC product programs through development and into clinical trials by providing them with direct access to Albany Molecular's manufacturing expertise.'

'We are pleased to extend our partnership with Seattle Genetics in the growing therapeutic area of antibody-drug conjugates by supporting the drug-linker manufacturing campaigns of their licensees,' commented Dr Thomas D'Ambra, AMRI chairman, chief executive officer and president. 'This agreement is an important strategic initiative for Albany Molecular Research that recognises our advanced synthesis and cGMP manufacturing capabilities.'